Lymph node mapping and sentinel node detection in patients with cervical carcinoma: a 2-year experience

Area of Science:

• Gynecologic Oncology
• Surgical Pathology
• Cancer Staging

Background:

• Cervical cancer staging traditionally involves pelvic lymphadenectomy, which can lead to significant morbidity.
• Sentinel lymph node biopsy (SLN) offers a potentially less invasive method for staging by identifying the first lymph nodes to receive drainage from the tumor.

Purpose of the Study:

• To evaluate the feasibility and accuracy of sentinel lymph node biopsy using a laparotomic approach with blue dye injection in patients with cervical cancer.
• To assess the detection rate and false-negative rate of SLN biopsy in this patient population.

Main Methods:

• A prospective observational study involving 50 patients with FIGO stage IA2 to IIA cervical cancer.
• Intracervical injection of methylene blue dye for SLN mapping, followed by radical abdominal hysterectomy and pelvic lymphadenectomy.
• Pathologic evaluation of SLNs included serial sectioning and cytokeratin immunohistochemistry.

Main Results:

• A 90% SLN detection rate per patient was achieved, with a 72% detection rate per side of dissection.
• Lymph node metastases were found in 20% of patients, with one false-negative SLN result.
• The false-negative rate was 10% per patient and 8.3% per side, with a high negative predictive value (97.2% per patient).

Conclusions:

• Sentinel lymph node biopsy with blue dye is a feasible and effective surgical staging procedure for cervical cancer, particularly in young patients with early-stage tumors.
• The technique demonstrates a high detection rate and acceptable false-negative rates, suggesting its potential utility in reducing surgical morbidity.
• Further research is needed to confirm the long-term morbidity-sparing benefits of SLN biopsy in cervical cancer management.